头孢噻肟钠/他唑巴坦钠治疗急性细菌性下呼吸道感染对患者血清PCT、CRP和SAA水平的影响

Effect of cefotaxime sodium/tazobactam sodium on serum PCT, CRP and SAA levels in the treatment of acute bacterial lower respiratory tract infection

目的探讨头孢噻肟钠/他唑巴坦钠治疗急性细菌性下呼吸道感染的临床疗效及其对患者血清降钙素原(PCT)、C-反应蛋白(CRP)和淀粉样蛋白A (SAA)水平的影响。方法回顾性分析2017年6月至2018年5月榆林市第二医院呼吸内科治疗的82例急性细菌性下呼吸道感染患者的临床资料,根据给药方式的不同分为观察组和对照组,每组41例。对照组给予莫西沙星治疗,观察组给予头孢噻肟钠/他唑巴坦钠治疗,两组均治疗1周。比较两组患者的治疗疗效、细菌学疗效、不良反应发生情况以及治疗前后的血清PCT、CRP和SAA水平。结果观察组患者的治疗总有效率为92.68%,明显高于对照组的75.61%,差异有统计学意义(P<0.05);治疗后两组患者的血清WBC、CRP、PCT、SAA水平均较治疗前下降,且观察组的下降水平均较对照组更明显,差异均有统计学意义(P<0.05);观察组患者的细菌清除率为93.02%,明显高于对照组的76.19%,差异有统计学意义(P<0.05);观察组患者的不良反应总发生率为9.76%,与对照组的7.32%比较差异无统计学意义(P>0.05)。结论头孢噻肟钠/他唑巴坦钠治疗急性细菌性下呼吸道感染患者临床疗效显著,且可有效降低血清PCT、CRP和SAA水平。

Objective To investigate effect of cefotaxime sodium/tazobactam sodium on serum procalcitonin(PCT), C-reactive protein(CRP) and serum amyloid A(SAA) levels in the treatment of acute bacterial lower respiratory tract infection. Methods The clinical data of 82 cases of patients with acute bacterial lower respiratory tract infection,who admitted to Department of Respiratory Medicine of the Second Hospital of Yulin City from June 2017 to May 2018, were retrospectively analyzed. The patients were divided into the control group and the observation group according to the treatment methods. The control group received moxifloxacin, while the observation group was treated with cefotaxime sodium/tazobactam sodium. The patients in the two groups were treated for one weeks. The therapeutic efficacy, bacteriological efficacy, adverse reaction, the pre-and post-treatment serum PCT, CRP, SAA levels were compared. Results The total effective rate of treatment in the observation group was 92.68%, which was significantly higher than 75.61% of the control group(P<0.05). Serum WBC, CRP, PCT, and SAA levels in the two groups after treatment were decreased, and the extent of decrease in the observation group were significantly lower than those in the control group(all, P<0.05). The bacterial clearance rate of the observation group was 93.02%, which was significantly higher than 76.19% of the control group(P<0.05). The total incidence of adverse reactions in the observation group was9.76% versus 7.32% in the control group(P>0.05). Conclusion Cefotaxime sodium/tazobactam sodium can effectively reduce serum PCT, CRP and SAA levels for patients with acute bacterial lower respiratory tract infection.